Download in electronic PDF format for $65

Abstract:  Skin injuries, whether acute or chronic, can present therapeutic challenges engendered by wound type and etiology as well as the pharmacogenomic profile and treatment preferences of the patient. As a result, standardized manufactured medications may fail to promote healing or their use may prove intolerable (complications that impose a burden on patients and ultimately on the society in which they live and the healthcare system that supports them). For cases in which commercially available wound-healing products fail or cannot be used, a uniquely formulated pharmaceutical compound may be effective. In this article, the differences between acute and chronic dermal injuries are presented, wound infection is discussed, specific compounds designed to treatment some of the most challenging dermal-wound types are listed, and two complete formulations that have also proven safe and effective in promoting the healing of external skin damage are provided.

Related Keywords: Mike Riepl, RpH, wound healing, acute wounds, chronic wounds, inflammation, inflammatory cytokines, inflammatory mediators, skin breakdown, cytolytic enzymes, formulations, topical preparations, transdermal administration, liothyronine sodium, timolol maleate, wound infection, burns, phenytoin, misoprostol, lidocaine hydrochloride, gentamicin, arginine hydrochloride, aloe vera, insulin, chronic venous stasis ulcers, gabapentin, ketamine hydrochloride, prilocaine, naltrexone hydrochloride, ketoprofen, sildenafil, metronidazole

Related Categories: DERMATOLOGY, FORMULATIONS, WOUND CARE, DOSAGE FORMS/DRUG CARRIERS, INFECTIOUS DISEASE

Printer-Friendly Version